Shandong Boan Biotechnology Past Earnings Performance
Past criteria checks 0/6
Shandong Boan Biotechnology has been growing earnings at an average annual rate of 4.1%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 54.9% per year.
Key information
4.1%
Earnings growth rate
131.7%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 54.9% |
| Return on equity | -9.0% |
| Net Margin | -19.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Shandong Boan Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 618 | -119 | 308 | 231 |
| 30 Sep 23 | 587 | -209 | 305 | 294 |
| 30 Jun 23 | 557 | -298 | 302 | 357 |
| 31 Mar 23 | 536 | -315 | 299 | 379 |
| 31 Dec 22 | 516 | -332 | 296 | 400 |
| 30 Sep 22 | 442 | -291 | 253 | 345 |
| 30 Jun 22 | 367 | -251 | 211 | 289 |
| 31 Mar 22 | 263 | -238 | 153 | 260 |
| 31 Dec 21 | 159 | -225 | 96 | 232 |
Quality Earnings: 6955 is currently unprofitable.
Growing Profit Margin: 6955 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 6955's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 6955's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6955 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).
Return on Equity
High ROE: 6955 has a negative Return on Equity (-9.04%), as it is currently unprofitable.